CSE: AIAI | OTCQB: AINMF | FRA: 8TV
Investor Presentation
Press Releases
September 15, 2023 – NetraMark Private Placement – Press Release Clarification
September 11, 2023 – NetraMark Announces Private Placement Financing
July 19, 2023 – Pharmaceutical Industry Veteran Joins NetraMark Advisory Board
July 5, 2023 – NetraMark Announces Shares for Debt Settlement
June 22, 2023 – NetraMark Enters into Advisor Agreement
June 21, 2023 – NetraMark Announces Engagement of ARU Global Inc.
June 14, 2023 – NetraMark Closes Second and Final Tranche of Private Placement
June 9, 2023 – NetraMark Closes First Tranche of Private Placement
June 7, 2023 – NetraMark Announces Uplist to the OTCQB Market
June 6, 2023 – NetraMark Announces Increase to Private Placement Financing
June 1, 2023 – NetraMark Announces Private Placement Financing
June 1, 2023 – NetraMark to Attend American Society of Clinical Oncology Conference in Chicago
May 30, 2023 – NetraMark to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Wednesday, May 31 and Wednesday June 7, 2023
May 16, 2023 – NetraMark, the First Public AI Company to Launch Clinical Trial De-Risking Technology that Integrates ChatGPT
May 9, 2023 – NetraMark engages ITG as Market Maker to enhance liquidity
May 5, 2023 – NetraMark retains Renmark Financial Communications Inc.
May 2, 2023 – NetraMark Successfully Delivers on Biopharma Client Contract
March 24, 2023 – NetraMark Announces Closing of Private Placement
March 21, 2023 – Healthcare Strategy Leader Joins NetraMark Advisory Board
March 15, 2023 – NetraMark Uncovers Unique Alzheimer’s Disease Subtypes
February 27, 2023 – NetraMark Releases Paper Demonstrating AI Capabilities to Derive Insights Using Clinical Scale Data
January 30, 2023 – Introducing NetraMark – A Pharma AI Company
Financial Releases
Sedar & Financial Reports
Corporate Documents
Corporate Governance
Odyssey Trust
[Transfer Agent]
United Kingdom Building 323
409 Granville Street
Vancouver, BC V6C 1T2